Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
